Q-omics provides the consensus-scored CDCA4P1 profile across patient tissues and cancer cell-line models. CDCA4P1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CDCA4P1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CDCA4P1 RNA expression shows 18,468 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, THCA, and THYM as cancer lineages where CDCA4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCA4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCA4P1 survival associations across molecular data types. CDCA4P1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCA4P1 RNA expression–survival associations across cancer types. High CDCA4P1 expression shows unfavorable associations in UCEC and MESO, but favorable associations in BRCA, LUAD, UCS and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for CDCA4P1 RNA expression.
This table summarizes CDCA4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDCA4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCA4P1 shows lower tumor expression in THCA, UCEC, BRCA, READ and LUSC and higher tumor expression in CHOL. The THCA box plot shows higher CDCA4P1 RNA expression in normal versus tumor tissue (log2 FC = −0.298, t-test p < 0.001).
This table shows molecular features associated with CDCA4P1 in patient tissues and cancer cell lines. In patient samples, CDCA4P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
